H. Pylori Infection and AIP Levels (HP-AIP)

Helicobacter Pylori Infection as A Potential Risk Factor for Dyslipidemia: Insights From Atherogenic Index of Plasma (AIP)

Helicobacter pylori is a common bacterial infection of the stomach that can cause ulcers and other digestive problems. Recent studies suggest that this infection may also affect metabolism and blood fats (lipids), which are important for heart health. Changes in lipid levels, such as higher triglycerides and lower "good" cholesterol (HDL), can increase the risk of cardiovascular disease.

This study will examine whether H. pylori infection is linked to changes in lipid profiles, especially the Atherogenic Index of Plasma (AIP). AIP is a calculation based on triglycerides and HDL cholesterol that helps predict the risk of heart disease.

Study Overview

• Status: Completed
• Conditions: H Pylori Infection; Atherogenic Plasma Index
• Intervention / Treatment: Diagnostic test: urea breath test

• Study Type: Observational
• Enrollment (Actual): 300

Contacts and Locations

Study Locations

• Egypt
  • Tanta, Egypt
    • Faculty of medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Probability Sample

Study Population

Adult patients (≥18 years) attending the Gastroenterology Unit at Tanta University Hospitals (Egypt) and the Internal Medicine Department at Tadawi Hospital (Saudi Arabia). Participants will include both men and women diagnosed with or without H. pylori infection, recruited consecutively during routine clinical visits.

Description

Inclusion Criteria:

• Patients older than 18 years.
• Able to sign the written consent.
• Willing to participate in the research and undergo H. pylori testing. Exclusion criteria
• Unwilling to participate in the study.
• History of severe metabolic disorders.
• Taking medications that affect adipose tissue metabolism.
• History of gastric surgery.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Group 1A: H. pylori Positive - Normal AIP Group 1B: H. pylori Positive - Elevated AIP Group 2: H.	Diagnostic test: urea breath test; Participants will undergo a urea breath test to confirm H. pylori infection status. Fasting blood samples will be collected to measure triglycerides and HDL cholesterol, and the Atherogenic Index of Plasma (AIP) will be calculated.
Group 1A: H. pylori Positive - Normal AIP, 1B: H. pylori Positive - Elevated AIP, Group 2: H.	Diagnostic test: urea breath test; Participants will undergo a urea breath test to confirm H. pylori infection status. Fasting blood samples will be collected to measure triglycerides and HDL cholesterol, and the Atherogenic Index of Plasma (AIP) will be calculated.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Atherogenic Index of Plasma (AIP)	AIP is calculated as log10(triglycerides/HDL cholesterol).	Baseline (single fasting blood sample at enrollment).

Collaborators and Investigators

• Sponsor: Tanta University

Study record dates

Study Major Dates

• Study Start (Actual): January 2, 2025
• Primary Completion (Actual): February 18, 2025
• Study Completion (Actual): August 4, 2025

Study Registration Dates

• First Submitted: December 12, 2025
• First Submitted That Met QC Criteria: December 25, 2025
• First Posted (Actual): December 29, 2025

Study Record Updates

• Last Update Posted (Actual): December 29, 2025
• Last Update Submitted That Met QC Criteria: December 25, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Other Study ID Numbers: Helicobacter Pylori and AIP

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No